8-K: Keros Therapeutics CFO Resigns, Interim Appointed

Keros Therapeutics announced the resignation of CFO Keith Regnante, effective August 3, 2026, with Corporate Controller Annita Tanini stepping in as interim principal financial and accounting officer.

Summary

• Keith Regnante has resigned as Chief Financial Officer of Keros Therapeutics, Inc., with his departure effective August 3, 2026.
• Annita Tanini, currently Corporate Controller and Vice President, Finance, has been appointed as the interim principal financial officer and principal accounting officer, effective August 4, 2026.
• Mr. Regnante's resignation is voluntary and not due to any disagreements with the company regarding financial matters.
• The company is initiating a search for a new Chief Financial Officer.
• Ms. Tanini has been with the company in finance leadership roles since May 2019 and has prior experience at Avedro, Inc., Fiksu, Inc., and other companies.
• Ms. Tanini's compensation includes an annual base salary of $302,300 and eligibility for a target annual cash bonus of 30% of her base salary.
• In case of termination without cause or resignation for good reason, Ms. Tanini is eligible for six months of base salary and COBRA premium payments for up to six months.
• Mr. Regnante is entitled to accrued base salary, reimbursement of business expenses, and COBRA continuation coverage as per his employment agreement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While a CFO departure can introduce uncertainty, the smooth internal transition to an experienced executive and the lack of financial disagreements mitigate immediate concerns.

Positives

• Smooth transition with an experienced internal candidate, Annita Tanini, appointed as interim CFO.
• Mr. Regnante's departure is voluntary and not related to any financial disagreements, indicating no underlying accounting or reporting issues.
• Ms. Tanini has a strong finance background with over a decade of experience in leadership roles at various companies, including previous biotech experience at Avedro, Inc.

Negatives

• Departure of a key executive (CFO) can create uncertainty and require significant effort to replace.
• The company is initiating a search for a new CFO, which could take time and resources.

Risks

• Potential disruption to financial operations during the transition period.
• The search for a new CFO may be challenging in the current market, potentially leading to a prolonged interim period.

Future Outlook

The company is actively searching for a new Chief Financial Officer to fill the vacancy left by Mr. Regnante's departure.

Management Comments

• Mr. Regnante's resignation was voluntary and was not the result of any disagreement with the Company on any matter relating to the Company's accounting practices, financial statements, internal controls over financial reporting, operations, policies or practices.

Industry Context

StockSavvy.ai notes that executive transitions, particularly for CFO roles, are common in the biotechnology sector as companies mature or face strategic shifts. The ability to appoint an experienced internal candidate like Ms. Tanini can mitigate disruption.

Management Changes

Stakeholder Impact

• Shareholders: Potential short-term uncertainty regarding financial leadership, but mitigated by the experienced interim appointment and lack of financial disputes.
• Employees: May experience some adjustment to new financial leadership, but the continuity provided by Ms. Tanini should minimize disruption.
• Creditors/Suppliers: No immediate impact expected, as financial operations are expected to continue smoothly under interim leadership.

Next Steps

• Company to conduct a search for a new Chief Financial Officer.
• Annita Tanini to serve as interim principal financial officer and principal accounting officer.
• Filing of the Tanini Employment Agreement as an exhibit to the Form 10-Q for the quarter ending June 30, 2026.

Key Dates

Recommendation

The filing reports a routine executive transition with no negative financial implications. The appointment of an experienced interim CFO provides continuity, and the company is initiating a search for a permanent replacement. This event alone does not warrant a change in investment strategy.

Keywords

Chief Financial Officer, CFO Resignation, Interim CFO, Executive Transition, Financial Leadership, Corporate Controller, SEC Filing, 8-K